Form 4: Blueprint Medicines Director Divests All Equity Following Sanofi Merger Completion

Blueprint Medicines Corporation Director Habib J. Dable disposed of all common stock and stock options on July 17, 2025, as part of the company's merger with Sanofi, receiving $129.00 per share plus a contingent value right.

Summary

• Director Habib J. Dable reported changes in beneficial ownership of Blueprint Medicines Corp (BPMC) securities.
• The transactions occurred on July 17, 2025, coinciding with the effective time of the merger between Blueprint Medicines Corp and Rothko Merger Sub, Inc., an indirect wholly-owned subsidiary of Sanofi.
• A tender offer was completed to acquire all outstanding common stock for $129.00 per share in cash, plus one contractual contingent value right (CVR) per share.
• All outstanding restricted stock units (RSUs), whether vested or unvested, were cancelled and converted into the merger consideration.
• All common stock held by the reporting person was tendered in exchange for the merger consideration.
• All outstanding stock options, whether vested or unvested, became fully vested, were cancelled, and converted into the cash offer price (less the applicable exercise price) plus one CVR per share.
• Fifty percent of options issued in calendar year 2025 were converted into cash-based awards subject to continued vesting based on the cash offer price (less the applicable exercise price) plus one CVR.
• Following these transactions, Habib J. Dable beneficially owns 0 shares of common stock and 0 derivative securities of Blueprint Medicines Corp.
• The reporting person is no longer subject to Section 16 reporting obligations for Blueprint Medicines Corp.

Sentiment

Score: 7

Explanation: The sentiment is positive for the reporting person as they successfully monetized their equity holdings at the agreed-upon merger price, including contingent value rights. For the company, it marks the completion of a strategic acquisition.

Positives

• The reporting person successfully monetized their equity holdings, receiving $129.00 per share in cash for common stock and RSUs, plus one contingent value right (CVR) per share.
• Stock options, both vested and unvested, became fully vested and were converted into cash (offer price minus exercise price) and CVRs, allowing the director to realize value from their equity holdings.

Negatives

• The director no longer holds any direct beneficial ownership in Blueprint Medicines Corp following the merger, indicating a complete divestment of their equity stake.

Future Outlook

No specific future outlook or guidance is provided in this Form 4, as it reports a past transaction related to a completed merger.

Industry Context

This Form 4 reflects the finalization of a significant acquisition in the biopharmaceutical industry, where a larger pharmaceutical company (Sanofi) acquires a smaller, specialized biotech firm (Blueprint Medicines). Such mergers are common for larger players to expand their pipeline or market share.

Comparison to Industry Standards

• This document reports a specific insider transaction related to a merger, not operational results. Therefore, direct comparison to industry standards for performance metrics is not applicable.
• The acquisition price of $129.00 per share plus CVRs would typically be compared to other biotech acquisitions in terms of valuation multiples (e.g., revenue multiples, pipeline value), but this document does not provide sufficient information for such a detailed comparative analysis.

Management Changes

Stakeholder Impact

• Shareholders: All public shareholders received $129.00 per share in cash plus one CVR, providing a clear exit strategy and value realization.
• Employees: Employees holding RSUs and stock options also had their equity converted into cash and CVRs, providing liquidity.
• Company (Blueprint Medicines): Now operates as an indirect wholly-owned subsidiary of Sanofi, losing its independent public listing.

Key Dates

Keywords

Blueprint Medicines, BPMC, Sanofi, Merger, Acquisition, Tender Offer, Form 4, SEC Filing, Insider Transaction, Stock Options, RSU, Contingent Value Right, CVR, Director, Equity Disposal